Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Harvard Scientific (HVSF)Hot$$- male impotency medicine -- Ignore unavailable to you. Want to Upgrade?

To: Green Hornet who wrote (3692)	7/7/1998 5:05:00 PM
From: Green Hornet	Read Replies (1) \| Respond to of 3906

Vivus: fast.quote.com The shorts are beginning to get incinerated in Vivus. Too bad that isn't happening to the shorts in HVSF (read Molson & Springrange). Any guesses as to what their respective average short prices are? As long as their shorts were not initiated subsequent to Jan 1 of this year, then their averages are above one dollar. Probably far above. Assuming Springrange averaged down from the high of 80, then its average short price would be $40 ($80 divided by 2). We've got a long way to go. But this is a start. Perhaps when the actual "major pharmaceutical company" announcement is made, the price will soar and Molson & Springrange (is there a connection between these two) will be incinerated. On the other hand, if it is a case of buy on the rumor, sell on the news, well . . . Molson & Springrange probably don't have anything to worry about. Green Hornet